Seed · Raised $171K · Jul 3, 2026announcement ↗
ALP Bio
Backed by
Healthtechalp.bio ↗
What they do
ALP Bio is developing an AI-powered platform to help drug developers evaluate immunogenicity risks associated with therapeutic antibodies earlier in the development process. Their technology utilizes tonsil organoid data and protein AI to enhance the accuracy of assessments and minimize adverse immune reactions.
Hiring outlook
With a seed round of $171,000, ALP Bio may be looking to bring on founding engineers and data scientists to build their platform, as well as potential regulatory and business development roles to support early-stage growth.
Open roles
No open roles on their board right now.